Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Can you explain in layman's terms what going to ph

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155125
(Total Views: 540)
Posted On: 11/04/2024 5:20:21 PM
Posted By: ohm20
Re: nelsonsjavaheads #147787
Quote:
Can you explain in layman's terms what going to phase II means for LL and CYDY.

What % of drugs make it that far and what % advance beyond that? Things along those lines.



I don't think percentage that get that far or progress further is a good metric for leronlimab. Phase 1 trials are focused on safety. As long as a drug isn't killing people or making them seriously ill and there is a narrative of why it might work in a disease it can go on to a Phase 2. A lot of those narratives are based on a weak set off facts and the drugs fail badly in the phase 2 so never go on to a Phase 3.

Even after being put on a safety hold for 2 1/2 years leronlimab isn't doing a Phase 1, our safety is impeccable. Studies and trials with CCR5 and cancer including our own prove out the mechanism of action. Getting a Phase 2 for mssCRC was obvious it was just a matter of quibbling over details. With a high expression of CCR5 in mssCRC and a proven MOA the only things I can see that would stop an advance to Phase 3 would be a very small patient population or skewed patient balance. CCR5 delta 32 double allele deletion patients should be excluded. If single allele deletion patients are allowed they must be balanced between arms.


(23)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us